Radisys Introduces Programmable Media Analytics to Monetize 5G & Edge Cloud Applications
23.2.2023 16:00:00 EET | Business Wire | Press release
Radisys® Corporation, a global leader of open telecom solutions, today announced the addition of Engage Media Analytics within the acclaimed Engage Digital Platform (EDP). Engage Media Analytics is a comprehensive solution that provides Communication Service Providers (CSPs), System Integrators, and Enterprises with cost-effective low-code/no-code visual design tools to create Industry 4.0 applications with new AI-powered audio analytics and computer vision capabilities.
Engage Media Analytics’ application possibilities include notifying medical personnel when a patient in a wheelchair needs assistance or an elderly at-home patient has fallen from the bed; or identifying critical keywords or background sounds on an emergency call to augment the live agent discussion and help make life-saving decisions; detecting a fire in a factory, campus building, or other location and alerting emergency services personnel; monitoring retail shelves and combing customer identification, location, and live video to send money saving coupons to a frequent shopper’s phone as they near a location with promotional items; and many other Industry 4.0 services.
The Engage Media Analytics solution offers a unique combination of capabilities:
- Off-the-shelf models including people and object counting, object and sound detection and classification, and biometric authentication. Engage Media Analytics also supports model customization and new model creation.
- Ability to create trigger actions based on insights derived from the media stream whether through other communication capabilities in the EDP, including voice and video calling, creating an on-the-fly conference, sending alerts, and recording, as well as interworking with external systems for initiating business processes in enterprise workflow tools.
- Distributed deployment of services spanning public and private clouds, network edge infrastructure, and on enterprise premises, enabling applications that demand low latency, cost and bandwidth-efficient network utilization for local breakout, and ensuring data privacy and security.
Alan Quayle, Founder TADHack, TADSummit, said: “The programmable communications industry (CPaaS) is evolving from a focus on connectivity to understanding the content of communications through programmable media analytics. Actionable intelligence and compliance are important in delivering innovative new services. The all-in-one Engage Digital Platform delivers AI-based actionable intelligence that enables service providers to deliver business efficiencies for their customers' mission-critical applications.”
Radisys’ Engage Media Analytics can be deployed on distributed edge cloud and integrates with public or private 4G/5G RAN and core network functions such as Network Exposure Function (NEF), abstracting complexities for application developers to productize Industry 4.0 applications quickly and cost-effectively.
Al Balasco, Head of Media and Application Solutions, Radisys, said: “The convergence and simultaneous maturity of multiple technologies like AI-based computer vision, 5G, edge cloud, and programmable communications opens new opportunities for service providers and system integrators to collaborate with enterprises in their digital transformation. Engage Media Analytics lets service providers combine the advantages of the bandwidth, low latency, Internet of Things (IoT) connectivity, and edge cloud resources to monetize public and private 5G networks and deliver customized solutions like predictive surveillance in smart cities, remote monitoring of enterprise campuses, business workflow automation for product quality assurance, traffic monitoring, and more.”
About Radisys
Radisys, a global leader in open telecom solutions, enables service providers to drive disruption with new open architecture business models. Radisys’ innovative disaggregated and virtualized enabling technology solutions leverage open reference architectures and standards, combined with open software and hardware to power business transformation for the telecom industry, while its world-class services organization delivers systems integration expertise necessary to solve communications and content providers’ complex deployment challenges. For more information, visit www.radisys.com.
Radisys’ Engage Digital Platform is an award-winning programmable communications platform. Radisys' capacity-based versus consumption-based licensing approach for all products in the Engage Digital Platform offers a truly disruptive economic model relative to alternative programmable communications solutions. It dramatically improves the total cost of ownership (TCO) savings to 70% and greater over competitive cloud-based programmable communications and video analytics solutions, allowing service providers to reap the benefits.
For more information, visit www.engagedigital.ai.
Radisys® is a registered trademark of Radisys. All other trademarks are the property of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230223005336/en/
Contact information
Nereus for Radisys
Matt Baxter, +1-503-619-0505
radisys@nereus-worldwide.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom